Skip to main content
. 2023 Feb 14;72(8):1581–1591. doi: 10.1136/gutjnl-2022-328708

Table 4.

Description of models to predict risk of mortality at several time points and their predictive ability in patients diagnosed with or without ACLF in the CANONIC (discovery set) and the PREDICT (validation set) study cohorts

Model C-index
At 7 days At 14 days At 28 days At 60 days At 90 days
AD-ACLF patients
Discovery set: CANONIC study cohort (n=181)
 % of deaths 7.73% 18.23% 26.52% 35.91% 40.33%
 CLIF-C MET 1 0.868 0.844 0.794 0.757 0.744
 CLIF-C MET 2 0.875 0.872 0.819 0.791 0.772
 CLIF-C ACLF score 0.757*† 0.793† 0.760† 0.734 0.720†
 MELDNa score 0.671*†‡ 0.711*†‡ 0.696*†‡ 0.707† 0.703†
Validation set: PREDICT study cohort (n=109)
 % of deaths 4.59% 16.51% 27.52% 34.86% 37.61%
 CLIF-C MET 1 0.914 0.724 0.717 0.714 0.714
 CLIF-C MET 2 0.892 0.730 0.733 0.722 0.721
 CLIF-C ACLF score 0.879 0.763 0.728 0.683† 0.670*†
 MELDNa score 0.601*†‡ 0.592*†‡ 0.644*†‡ 0.649*† 0.643*†
AD-no ACLF patients
Discovery set: CANONIC study cohort (n=650)
 % of deaths 0.92% 2.31% 4.77% 9.85% 12.46%
 CLIF-C MET 1 0.916 0.871 0.781 0.764 0.741
 CLIF-C MET 2 0.942 0.895 0.787 0.750 0.729
 CLIF-C AD score 0.768*† 0.769*† 0.752 0.733 0.736
 MELDNa score 0.715*† 0.686*†‡ 0.693*†‡ 0.723 0.723
Validation set: PREDICT study cohort (n=742)
 % of deaths 0.67% 2.83% 6.06% 12.40% 15.36%
 CLIF-C MET 1 0.928 0.841 0.769 0.769 0.760
 CLIF-C MET 2 0.945 0.864 0.781 0.769 0.759
 CLIF-C AD score 0.839*† 0.798† 0.723 0.715 0.707
 MELDNa score 0.757*†‡ 0.726*†‡ 0.694*† 0.668*† 0.660*†‡

*P value <0.01 compared to the metabolomic model 1 for differences larger than 0.05.

†P value <0.01 compared to the metabolomic model 2 for differences larger than 0.05.

‡P value <0.01 compared to the CLIF-C ACLF/CLIF-C AD score for differences larger than 0.05.

ACLF, acute-on-chronic liver failure; AD, acutely decompensated cirrhosis; CLIF-C ACLF, Chronic Liver Failure Consortium ACLF.